Meet The Team
Kathryn A. Phillips, PhD
Chair and Founding Member
University of California San Francisco
San Francisco, California, USA
Organization Profile
Kathryn is the founding director of the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) in the School of Pharmacy at the University of California, San Francisco (UCSF). She is also a professor of health economics and health services research in the Department of Clinical Pharmacy at UCSF, with additional appointments in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center. Kathryn is a health services researcher and health economist who focuses on issues around access, quality, and value of new technologies. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Her particular interests are in coverage and reimbursement, decision-making, evidence synthesis, economic evaluation, and policy analysis for precision medicine.
James Buchanan, DPhil
James is a Senior Researcher in the Health Economics Research Centre at the University of Oxford. He primarily works on health economics projects in the area of genomic testing, including economic evaluations and stated preference studies. This work spans multiple clinical specialties, including cancer (chronic lymphocytic leukaemia, bowel cancer), rare diseases, infection control practice, screening and inflammatory bowel disease. His DPhil (PhD) work investigated issues related to the economic analysis of genomic diagnostic technologies for multifactorial genetic diseases in the UK NHS, based on a study evaluating genomic testing in haematological cancers. Alongside this academic work, James curates the Health Economics and Genomics blog.
Deborah A. Marshall, PhD
Deborah holds a Canada Research Chair, Health Services and Systems Research as a Professor at the University of Calgary and Arthur J.E. Child Chair of Rheumatology Outcomes Research in the McCaig Institute of Bone and Joint Health. She is the Director of Health Technology Assessment at the Alberta Bone and Joint Health Institute, a Senior Scientist at Arthritis Research Canada, and a member of the OBrien Institute of Public Health. Deborah has experience in technology assessment agencies, academia and pharmaceutical and diagnostics industry research settings in Canada, the United States, and Europe. Her research program focuses on patient preferences and patient engagement research, cost-effectiveness analysis, and dynamic simulation modeling of health services delivery to improve the effectiveness and efficiency of health care services. Deborah is an active member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) as the Past President of the Board of Directors.
Dean A. Regier, PhD
Founding Member
Cancer Control Research, BC Cancer; University of British Columbia
Vancouver, British Columbia, Canada
Organization Profile
Dean is a Senior Scientist within Cancer Control Research, BC Cancer and the Canadian Centre for Applied Research in Cancer Control (ARCC), and an Associate Professor, School of Population and Public Health, University of British Columbia. Dean’s research focuses on improving methods to estimate preference-based utility, with applications to genetic and genomic technologies and the ‘value of genomic knowledge’ i.e. how genes play a role in our personal lives and how publics value and trade between benefits and risks when making decisions to undergo genomic testing. He incorporates this person-centered evidence into economic models that answer questions of value for money. Dean’s contributions to health economics include publications in the areas of econometric analysis of discrete choice data, incorporating willingness to pay into probabilistic decision analytic models, and combining insights from experimental design and behavioral economics to improve the statistical efficiency of discrete choice models. His applied work consists of economic evaluations alongside clinical trials and machine learning methods to generating synthetic control cohorts.
Sarah A. Wordsworth, PhD
Sarah is an associate professor and university lecturer in the Nuffield Department of Population Health, Medical Sciences Division. Sarah joined the Health Economics Research Centre (HERC) in January 2003 and has developed a research program within HERC on the economics of genetic and genomic technologies. Of particular interest are the economics of translating genomic high-throughput technologies from research into clinical practice, in both cancer and cardiovascular disease. Sarah's other interests include costing methodology and trial-based evaluations in the areas of eye disease, blood transfusion, cardiac surgery and surgery for obesity.
Kurt D. Christensen, PhD, MPH
Affiliate Member
Harvard Pilgram Health Care Institute
Boston, Massachusetts, USA
Organization Profile
Kurt is an Assistant Professor at the Harvard Pilgrim Health Care Institute and Harvard Medical School whose research focuses on the medical, behavioral, and economic impact of integrating genomic tools into clinical and research settings. He has been an investigator on numerous high-profile NIH-funded studies of genomic information disclosure. His published work has not only provided some of the earliest insight about the implications of population genomic screening for health systems, providers, and patients, but also about the best methods for examining these issues. Kurt addresses these issues by focusing on three interrelated questions: 1) How do patients and physicians respond, behaviorally and psychologically, to information generated from emerging genomic technologies like whole genome sequencing? 2) What is the healthcare service and economic impact of integrating genomics into the everyday practice of medicine? 3) How can programs be improved to maximize the benefits and minimize the harms of genomic testing? The answers to these questions are essential as healthcare providers and policymakers make decisions about how to offer and support new genomic services.
Patricia A. Deverka, MD, MS
Affiliate Member
Deverka Consulting LLC.
Chapel Hill, North Carolina, USA
Patricia is the Executive Director at Deverka Consulting, LLC where she focuses on helping biotechnology companies and start-ups develop evidence to support payer coverage and clinical adoption of innovative technologies. Her most recent projects have focused on breakthrough tests and drugs focused on population genomic screening, cancer and ultra-rare disorders. Prior to starting her consulting practice, she has worked in the fields of health economics and outcomes research in both non-profit and for-profit settings as a researcher, educator, consultant, and department head. She has extensive experience with drug and diagnostic product development, reimbursement planning, cost- effectiveness analysis, and bioethical issues surrounding the use of new technologies. While working in academia and several non-profit firms, she has participated in numerous NIH-funded studies to evaluate policy barriers to clinical integration of new genomic technologies, and has published extensively on strategies to promote evidence generation and data sharing. She has a medical degree from the University of Pittsburgh and is board certified in General Preventive Medicine and Public Health. She also has a master’s degree in bioethics from the University of Pennsylvania and completed a policy fellowship at Duke University’s Institute for Genome Sciences and Policy.
Jeroen P. Jansen, PhD
Affiliate Member
University of California San Francisco
San Francisco, California, USA
Organization Profile
Jeroen is Associate Professor in the Department of Clinical Pharmacy at UCSF. Jeroen is a senior member of the TRANSPERS team and working, primarily as a methodologist, at the intersection of evidence synthesis, biostatistics, and health economics. Jeroen has 15 years of research experience and has led or supervised numerous projects to understand the value of healthcare technologies. Prompted by the challenges encountered in applied research projects, he has performed methodological research. Notable contributions are the development of novel statistical methods to overcome the typical challenges in model-based cost-effectiveness evaluations characterized by gaps in the evidence base and complex evidence structures. Furthermore, Jeroen led initiatives to develop guidance for consumers and producers of network meta-analysis studies. He has promoted a more transparent and credible approach to model-based health economic evaluations and led the development of open-source simulation models to illustrate its feasibility. Furthermore, Jeroen has been involved in the ongoing development of an R software package to develop simulation models for health economic evaluations. His current research interests are the clinical and economic value of precision medicine, incorporating novel elements of value and health disparities in health economic modeling studies, and statistical methods for evidence synthesis.
Julia R. Trosman, PhD
Affiliate Member
Center for Business Models in Healthcare, a practice of Executive Frameworks, Ltd.
Chicago, Illinois, USA
Julia is the Director and Co-Founder, Center for Business Models in Healthcare, a practice of Executive Frameworks, Ltd, a health services research organization focused on researching, developing and implementing innovative models for collaborative care delivery, adoption of medical and care innovation, and reimbursement. She is also an Assistant Adjunct Professor, TRANSPERS, Department of Clinical Pharmacy, University of California San Francisco, and Assistant Adjunct Professor, Feinberg School of Medicine, Northwestern University, Chicago, IL. Julia’s research is focused on the area of precision medicine insurance coverage and reimbursement, with an emphasis on payer coverage decision-making. In collaboration with TRANSPERS, she has conducted innovative primary research with the largest US private payers on factors and criteria of coverage for novel genomic technologies since 2007. The research has focused on a spectrum of relevant diseases (e.g., cancer, prenatal genetic disorders, pediatric developmental and neurologic disorders) and clinical settings (e.g., hereditary syndrome risk assessment in asymptomatic populations and disease management setting).
Maarten IJzerman, PhD
Maarten is professor and Chair of Cancer Health Services Research in the University of Melbourne Centre for Cancer Research and the Centre for Health Policy of the Melbourne School of Population and Global Health. He also maintains a position as a Health Technology Assessment professor at the University of Twente (Netherlands) and is an honorary professorial fellow in the Peter MacCallum Cancer Centre. His international work in Europe, Canada and Australia focuses on the health economics and health services implications of personalized medicine, including research on drug treatment sequencing and the use of complex genomic sequencing. He has been a leader in projects investigating the clinical use of liquid biopsies in cancer management and the use of whole-genome sequencing in NSCLC and blood cancers. He is a health economics (co-) lead in projects developing prediction models in prostate cancer, an Australian program estimating economic impact of new cancer treatments, and in the Canadian-Dutch study investigating optimal and cost-effective treatment pathways in juvenile arthritis patients using genomics and artificial intelligence. He chairs the VCCC Value-Based Healthcare Program, sits on the Australian Medical Services Advisory Committee and is a member of numerous (inter-) national advisory boards related to health services research, clinical governance, and cancer management and innovation.
Ilias Goranitis, PhD
Ilias is an Associate Professor in Health Economics at the University of Melbourne and the Health Economics Lead of Australian Genomics. His work focuses on exploring the value and cost-effectiveness of genomic technologies using health economic and discrete choice modelling. Ilias has been a successful co-applicant in research grants worth over AU$50 million, and his work has been published in top-tier journals including the New England Journal of Medicine, Lancet Global Health, Genetics in Medicine, and Value in Health. He provides advice on the prioritization of genomics and genomics research internationally and coordinates the University of Melbourne Health Economics Group, which a cross-faculty network of over 50 health economists.
Geert Frederix, PhD
Geert is an Associate Professor in Health Technology Assessment (HTA) and currently head of the HTA department at the University Medical Center Utrecht, the Netherlands. In addition, he is member of the steering group of The Health care INnovation Centre (THINC.) at the UMC Utrecht and an active member of the editorial board of PharmacoEconomics – Open. Geert has experience in pharmaceutical, diagnostic and medical device related HTA assessments. His research program focusses on (early) economic evaluation of biomedical innovations. He has extensive experience in assessing added value of genomic technologies in both rare disease and oncology and is involved in several national and international working groups discussing the added value of genomic technologies. He has collaborated on numerous previous and current grants from the Dutch government on this topic. One of his professional goals is to develop methodologies adequately reflecting added value of genomic technologies.
Hadley Stevens Smith, PhD, MPSA
Hadley is a postdoctoral fellow in Health Policy in the Center for Medical Ethics and Health Policy at Baylor College of Medicine. She earned a PhD in Health Economics from the University of Texas Health Science Center School of Public Health and also holds a Master of Public Service and Administration with a concentration in Health Policy Analysis from the Bush School of Government and Public Service at Texas A&M University and a Bachelor of Science in Political Science with a minor in Genetics. She has extensive professional training in Genetics, including a Certificate in Genetics and Genomics from the Stanford Center for Professional Development and ongoing participation in multiple seminars and grand rounds at Baylor College of Medicine. Her research is at the intersection of health economics and the ethical, legal, and social implications (ELSI) of genomic medicine. She is interested in measurement of outcomes of genomic sequencing, development and application of tools to measure utility in clinical genomics, and assessment of family-level impacts and cascade screening.
Wendy J. Ungar, MSc, PhD
Affiliate Member
Hospital for Sick Children Research Institute, University of Toronto
Toronto, Ontario, Canada
Organization Profile
Wendy is a Senior Scientist, Child Health Evaluative Sciences, Hospital for Sick Children Research Institute, Professor, Institute of Health Policy, Management and Evaluation, University of Toronto, and Affiliate Scientist, Institute for Clinical Evaluative Sciences (IC/ES). She holds a Tier 1 Canada Research Chair in Economic Evaluation and Technology Assessment in Child Health. In 2007 Wendy founded TASK (Technology Assessment at Sick Kids), where she and her team conduct research applying health economic methods to child health with a focus on genomics and neurodevelopmental disorders. She and her team maintain the PEDE database, a user-friendly online database of pediatric economic evaluations published since 1980 used by HTA agencies around the world. She chairs the Ontario Genetic Testing Advisory Committee which makes funding recommendations on emerging genetic testing technologies for Ontario. Her book, Economic Evaluation in Child Health was published by Oxford University Press in 2010.
Michael P. Douglas, MS
Managing Director
University of California San Francisco
San Francisco, California, USA
Organization Profile
Michael is the Managing Director for GEECS and the Program Manager for TRANSPERS. Michael has worked with Kathryn Phillips, TRANSPERS Founder and Director, and other personalized medicine investigators for over 20 years in varying organizations, including the Centers for Disease Control and Prevention’s Office of Public Health Genomics, Blue Cross Blue Shield Association’s Technical Evaluation Center, and Bayer Diagnostics. His research spans a variety of disciplines, including clinical and social sciences, in the academic, government, and industry sectors. He has extensive expertise in genomic laboratory medicine, evidence-based reviews of molecular-based testing, personalized medicine, and research program management. As GEECS Managing Director, he leads the administrative aspects of GEECS including infrastructure development and has a research role in some GEECS research projects. As TRANSPERS Program Manager, he has a leadership role in several grants, research and research development, program management, and publication.